Head-to-head evidence
Hemay005 vs HPP737
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
Hemay005
Developed by Tianjin Hemay Pharmaceutical
NCT04839328 · Phase 3 · completed
The study randomized 306 participants to Hemay005 or placebo, with participants masked to treatment, and used the clinical PASI75 response as its primary endpoint. Because no comparative results or statistical analysis are posted, the primary endpoint cannot be assessed.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
HPP737
Developed by Newsoara Biopharma
NCT07712731 · Phase 3 · completed
The trial randomized 607 participants to HPP737 or active treatment with apremilast and used triple masking of participants, care providers, and investigators. Its primary endpoints were clinical psoriasis measures, but the treatment comparison cannot yet be judged because the registry has not posted results.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hemay005's landscape · HPP737's landscape